Appendix 3 (as supplied by authors): Compliance to Guideline Endpoints – Patient Level Per-Protocol Analysis

	Pre-implementation		**Post-implementation**		**Between-group Comparisons - P Value[γ]**			
Guideline	**Experimental Group**	**Control Group**	**Experimental Group**	**Control Group**	**(1)**	**(2)**	**(3)**	**(4)**
Primary Outcome								
Endoscopic hemostasis followed by high-dose IV PPI	12/95 (12.6%)	11/155 (7.1%)	7/89 (7.9%)	6/124 (4.8%)	.369	.337	.992	.867
Secondary Outcomes								
Injection and/or thermal coagulation without clips and bolus IV PPI followed by infusion for 72 hours for high-risk ulcers	7/95 (7.4%)	8/155 (5.2%)	4/89 (4.5%)	6/124 (4.8%)	.921	.857	.467	----
Injection and/or thermal coagulation stigmata with clips and bolus IV PPI followed by 8 mg/hr infusion for 72 hours & no oral PPI. If pre-endoscopy infusion, absence of bolus IV PPI post-endoscopy ignored.	65/95 (68.4%)	91/155 (58.7%)	50/89 (56.2%)	78/124 (62.9%)	.545	.259	.081	----
Injection and/or thermal coagulation with clips and Pre-endoscopy bolus of PPI plus 80-mg bolus IV PPI followed by 8 mg/hr infusion for 72 hours post-endoscopic therapy & no oral PPI.	2/95 (2.1%)	3/155 (1.9%)	1/89 (1.1%)	1/124 (0.8%)	.771	.681	.696	----
Injection and/or thermal coagulation upon endoscopy for high-risk ulcers with clips alone	78/95 (82.1%)	116/155 (74.8%)	67/89 (75.3%)	90/124 (72.6%)	.824	.800	.408	----
Injection and/or thermal coagulation without clips for high-risk ulcers alone	47/95 (49.5%)	87/155 (56.1%)	45/89 (50.6%)	58/124 (46.8%)	.776	.930	.968	----
80-mg IV bolus followed by 8 mg/hr PPI infusion for 72 hours post-endoscopic therapy & no oral PPI.	17/111 (15.3%)	17/170 (10.0%)	10/155 (10.5%)	24/151 (15.9%)	.553	.729	.518	.524
80-mg bolus IV PPI followed by 8 mg/hr infusion for 72 hours post-endoscopic therapy & no oral PPI. If pre-endoscopy infusion, absence of bolus IV PPI post-endoscopy ignored.	90/111 (81.1%)	136/170 (80.0%)	72/95 (75.8%)	135/151 (89.4%)	.022	.108	.119	----
Pre-endoscopy bolus of PPI plus 80-mg bolus IV PPI followed by 8 mg/hr infusion for 72 hours post-endoscopic therapy & no oral PPI.	2/111 (1.8%)	3/170 (1.8%)	1/95 (1.1%)	14/151 (9.3%)	.221	.198	.197	----

Appendix to: Barkun AN, Bhat M, Armstrong D, et al. Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. *CMAJ* 2013.
DOI:10.1503/cmaj.120095.

	Early endoscopy (in the first 24 hours) with risk classification by clinical/endoscopic criteria	146/240 (60.8%)	278/424 (65.6%)	130/228 (57.0%)	245/388 (63.1%)	.302	.212	.260	.085
	No hemostasis for low risk lesion	110/126 (87.3%)	223/238 (93.7%)	127/133 (95.5%)	218/245 (89.0%)	.171	.088	.026	----
	Endoscopic Hemostasis for adherent clot	22/23 (95.7%)	22/25 (88.0%)	14/18 (77.8%)	21/26 (80.8%)	.843	----	----	----
	Endoscopic Hemostasis for other active bleeding or visible vessel	95/114 (83.3%)	155/186 (83.3%)	89/95 (93.7%)	124/144 (86.1%)	.175	.118	.134	.164
	Low Risk Patients Treated	16/126 (12.7%)	15/238 (6.3%)	6/133 (4.5%)	27/245 (11.0%)	.171	.088	.026	-----
	Low Risk patients receiving IV PPI bolus or infusion post-endoscopy	78/126 (61.9%)	141/238 (59.2%)	75/133 (56.4%)	157/245 (64.1%)	.262	.360	.251	.239

(1) Site adjusted Chi-square for dichotomous outcomes, (2) covariate adjustment for baseline, bed size (≤400 vs >400), Ontario (yes/no) and interaction of bed size and Ontario. Adjustment for site has been made for p values in (4) using the generalized estimating equations (GEE) for dichotomous endpoints and mixed models for continuous endpoints.